166 related articles for article (PubMed ID: 24048333)
1. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.
Wistuba II; Behrens C; Lombardi F; Wagner S; Fujimoto J; Raso MG; Spaggiari L; Galetta D; Riley R; Hughes E; Reid J; Sangale Z; Swisher SG; Kalhor N; Moran CA; Gutin A; Lanchbury JS; Barberis M; Kim ES
Clin Cancer Res; 2013 Nov; 19(22):6261-71. PubMed ID: 24048333
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma.
Eguchi T; Kadota K; Chaft J; Evans B; Kidd J; Tan KS; Dycoco J; Kolquist K; Davis T; Hamilton SA; Yager K; Jones JT; Travis WD; Jones DR; Hartman AR; Adusumilli PS
Oncotarget; 2016 Jun; 7(23):35241-56. PubMed ID: 27153551
[TBL] [Abstract][Full Text] [Related]
3. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma.
Bueno R; Hughes E; Wagner S; Gutin AS; Lanchbury JS; Zheng Y; Archer MA; Gustafson C; Jones JT; Rushton K; Saam J; Kim E; Barberis M; Wistuba I; Wenstrup RJ; Wallace WA; Hartman AR; Harrison DJ
J Thorac Oncol; 2015 Jan; 10(1):67-73. PubMed ID: 25396679
[TBL] [Abstract][Full Text] [Related]
4. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators.
Rakha E; Pajares MJ; Ilie M; Pio R; Echeveste J; Hughes E; Soomro I; Long E; Idoate MA; Wagner S; Lanchbury JS; Baldwin DR; Hofman P; Montuenga LM
Eur J Cancer; 2015 Sep; 51(14):1897-903. PubMed ID: 26235745
[TBL] [Abstract][Full Text] [Related]
5. Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.
Chen L; Kurtyka CA; Welsh EA; Rivera JI; Engel BE; Muñoz-Antonia T; Yoder SJ; Eschrich SA; Creelan BC; Chiappori AA; Gray JE; Ramirez JL; Rosell R; Schabath MB; Haura EB; Chen DT; Cress WD
Oncotarget; 2016 Dec; 7(50):82254-82265. PubMed ID: 27756884
[TBL] [Abstract][Full Text] [Related]
6. Prediction of distant recurrence in resected stage I and II lung adenocarcinoma.
Aramini B; Casali C; Stefani A; Bettelli S; Wagner S; Sangale Z; Hughes E; Lanchbury JS; Maiorana A; Morandi U
Lung Cancer; 2016 Nov; 101():82-87. PubMed ID: 27794412
[TBL] [Abstract][Full Text] [Related]
7. Analytical validation of a proliferation-based molecular signature used as a prognostic marker in early stage lung adenocarcinoma.
Warf MB; Fosso PG; Hughes E; Perry M; Brown KL; Reid JE; Kolquist KA; Wagner S; Gutin A; Roa B
Biomark Med; 2015; 9(9):901-10. PubMed ID: 26158298
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
9. Gene-expression signature predicts postoperative recurrence in stage I non-small cell lung cancer patients.
Lu Y; Wang L; Liu P; Yang P; You M
PLoS One; 2012; 7(1):e30880. PubMed ID: 22292069
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.
Canter DJ; Reid J; Latsis M; Variano M; Halat S; Rajamani S; Gurtner KE; Sangale Z; Brawer M; Stone S; Bardot S
Eur Urol; 2019 Mar; 75(3):515-522. PubMed ID: 30391079
[TBL] [Abstract][Full Text] [Related]
11. Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer.
Gentles AJ; Bratman SV; Lee LJ; Harris JP; Feng W; Nair RV; Shultz DB; Nair VS; Hoang CD; West RB; Plevritis SK; Alizadeh AA; Diehn M
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26286589
[TBL] [Abstract][Full Text] [Related]
12. An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
Dama E; Melocchi V; Dezi F; Pirroni S; Carletti RM; Brambilla D; Bertalot G; Casiraghi M; Maisonneuve P; Barberis M; Viale G; Vecchi M; Spaggiari L; Bianchi F; Di Fiore PP
Clin Cancer Res; 2017 Jan; 23(1):62-72. PubMed ID: 27358486
[TBL] [Abstract][Full Text] [Related]
13. HOXA9 methylation and blood vessel invasion in FFPE tissues for prognostic stratification of stage I lung adenocarcinoma patients.
Lissa D; Ishigame T; Noro R; Tucker MJ; Bliskovsky V; Shema S; Beck JA; Bowman ED; Harris CC; Robles AI
Lung Cancer; 2018 Aug; 122():151-159. PubMed ID: 30032824
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer.
Chen DT; Hsu YL; Fulp WJ; Coppola D; Haura EB; Yeatman TJ; Cress WD
J Natl Cancer Inst; 2011 Dec; 103(24):1859-70. PubMed ID: 22157961
[TBL] [Abstract][Full Text] [Related]
15. A novel seven-long non-coding RNA signature predicts survival in early stage lung adenocarcinoma.
Chen M; Liu B; Xiao J; Yang Y; Zhang Y
Oncotarget; 2017 Feb; 8(9):14876-14886. PubMed ID: 28122330
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.
Cuzick J; Berney DM; Fisher G; Mesher D; Møller H; Reid JE; Perry M; Park J; Younus A; Gutin A; Foster CS; Scardino P; Lanchbury JS; Stone S;
Br J Cancer; 2012 Mar; 106(6):1095-9. PubMed ID: 22361632
[TBL] [Abstract][Full Text] [Related]
17. Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.
Buhl IK; Santoni-Rugiu E; Ravn J; Hansen A; Christensen IJ; Jensen T; Pratt B; Askaa J; Jensen PB; Knudsen S; Sørensen JB
PLoS One; 2018; 13(3):e0194609. PubMed ID: 29566065
[TBL] [Abstract][Full Text] [Related]
18. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
[TBL] [Abstract][Full Text] [Related]
19. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.
Martínez-Terroba E; Behrens C; de Miguel FJ; Agorreta J; Monsó E; Millares L; Sainz C; Mesa-Guzman M; Pérez-Gracia JL; Lozano MD; Zulueta JJ; Pio R; Wistuba II; Montuenga LM; Pajares MJ
J Pathol; 2018 Aug; 245(4):421-432. PubMed ID: 29756233
[TBL] [Abstract][Full Text] [Related]
20. Signaling pathway-based identification of extensive prognostic gene signatures for lung adenocarcinoma.
Wan YW; Beer DG; Guo NL
Lung Cancer; 2012 Apr; 76(1):98-105. PubMed ID: 22047960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
